Nasdaq Extends Akanda's Deadline to December 13 for Equity Compliance
AKAN has more than doubled off its 52-week low of $2.295.
Summary
Nasdaq granted Akanda an extension through December 13, 2026 to regain compliance with the minimum stockholders' equity requirement, following a deficiency notice received in June.
Key Events · Legal and Risk Events · AKAN
-
Nasdaq Extension Granted
Akanda received an extension through December 13, 2026 to regain compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.
-
Compliance Plan Submitted
The company submitted a plan to regain compliance on July 31, 2026, supplemented on August 12, 2026.
-
Delisting Risk Remains
There is no assurance Akanda will regain compliance; failure could result in delisting from Nasdaq.
Analysis · AKAN · Life Sciences
The Nasdaq extension gives Akanda until December 13, 2026 to regain compliance with the minimum stockholders' equity rule. The company had been notified on June 16, 2026 that it fell below the $2.5 million threshold. This extension provides more time to raise capital or restructure, but delisting risk remains if the requirement is not met by the deadline.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1447 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKAN was trading at $5.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $2.30 to $209.03. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.